Physician profile
Hunter Shrum
NPI 1346999554
$2,545.05
in general payments reported to CMS, 2019-2025
27 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,032 · 2023: $1,196 · 2024: $16.55 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $532.38 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $402.28 | 2022-2025 | |
| Lilly USA, LLC | $245.71 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Xeris Pharmaceuticals, INC. | $173.30 | 2022-2023 | Gvoke Hypopen |
| Pfizer INC. | $134.02 | 2023-2024 | |
| Glaxosmithkline, LLC. | $127.70 | 2022-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.54 | 2022-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $97.62 | 2022-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $89.22 | 2022 | |
| Corcept Therapeutics | $85.95 | 2022-2023 | Korlym |
| Teva Pharmaceuticals USA, INC. | $73.45 | 2022-2023 | Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $71.98 | 2022-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $61.56 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.28 | 2022-2023 | Jardiance |
| Amgen INC. | $36.89 | 2022-2025 | Krystexxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.67 | 2025 | Veozah |
| Impel Pharmaceuticals INC. | $33.79 | 2022-2023 | Trudhesa |
| Nestle Healthcare Nutrition INC. | $24.27 | 2022 | |
| Antares Pharma, INC. | $22.07 | 2025 | Xyosted |
| Shield Therapeutics INC | $21.95 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.36 | 2023 | Horizant |
| Phathom Pharmaceuticals, INC. | $20.04 | 2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $19.98 | 2022 | |
| Merck Sharp & Dohme LLC | $14.92 | 2022 | |
| Tolmar, INC. | $14.55 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $14.02 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Shrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.